可手术I期非小细胞肺癌影像引导质子治疗的长期生存结局与生活质量:一项2期研究
本单中心前瞻性2期研究纳入43例可手术的组织学确诊IA或IB期非小细胞肺癌患者,评估影像引导质子治疗的长期疗效、安全性及生活质量变化。外周病灶处方66 GyRBE/10次,中央病灶72.6 GyRBE/22次;3年总生存率95%,7年83%,局部控制率3年与7年均为95%,≥3级放射性肺炎仅1例(2%);整体生活质量保持良好,但约40%患者在3个月和24个月报告呼吸困难。
要点
- 可手术I期NSCLC接受影像引导质子治疗,3年总生存率95%,7年83%。
- 3年与7年局部控制率均为95%,疾病控制持久。
- ≥3级放射性肺炎仅1例(2%),未观察到其他≥3级不良事件。
核心结论
- 影像引导质子治疗对可手术I期非小细胞肺癌(尤其外周病灶)可提供有效的疾病控制和生存,毒性轻微,患者生活质量良好。
研究设计与样本
- 单中心前瞻性2期研究,纳入43例可手术、组织学确诊的IA或IB期非小细胞肺癌患者(UICC第7版),2013年7月至2021年1月入组,中位年龄68岁(范围47-79岁)。
- 外周病灶处方剂量为66 GyRBE/10次,中央病灶为72.6 GyRBE/22次。
- 主要终点为3年总生存率;次要终点包括疾病控制、毒性和生活质量评分变化。
主要发现
- 43例中41例(95%)为外周病灶,27例(63%)为IA期。
- 总生存率3年为95%(95%CI 83-99),7年为83%(66-92);局部控制率3年为95%(82-99),7年为95%(82-99);无进展生存率3年为86%(72-94),7年为77%(60-88)。
- 4例(9%)发生2级放射性肺炎,1例(2%)发生3级放射性肺炎;未观察到其他3级或以上不良事件。
- 生活质量分析中整体生活质量保持良好,但约40%患者在3个月和24个月报告呼吸困难。
临床怎么用
- 作者认为,影像引导质子治疗可为可手术I期非小细胞肺癌(尤其外周病灶)提供有效的疾病控制和生存,且毒性轻微、生活质量良好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: This study evaluated long-term efficacy, safety, and changes in quality of life (QOL) of patients after image-guided proton therapy (IGPT) for operable stage I non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: This single-institutional prospective phase 2 study enrolled patients with operable histologically confirmed stage IA or IB NSCLC (7th edition of UICC). The prescribed dose was 66 Gy relative biological effectiveness equivalents (GyRBE) in 10 fractions for peripheral lesions, or 72.6 GyRBE in 22 fractions for central lesions. The primary endpoint was the 3-year overall survival (OS). The secondary endpoints included disease control, toxicity, and changes in QOL score. RESULTS: We enrolled 43 patients (median age: 68 years; range, 47-79 years) between July 2013 to January 2021, of whom 41 (95 %) had peripheral lesions and 27 (63 %) were stage IA. OS, local control, and progression-free survival rates were 95 % (95 % CI: 83-99), 95 % (82-99), and 86 % (72-94), respectively, at 3 years, and 83 % (66-92), 95 % (82-99), and 77 % (60-88), respectively, at 7 years. Four patients (9 %) developed grade 2, and one patient (2 %) developed grade 3 radiation pneumonitis. No other grade 3 or higher adverse events were observed. In the QOL analysis, global QOL remained favorable; however, approximately 40 % of patients reported dyspnea at 3 and 24 months. CONCLUSION: Our findings suggest that IGPT provides effective disease control and survival in operable stage I NSCLC, particularly for peripheral lesions. Moreover, toxicity associated with IGPT was minimal, and patients reported favorable QOL.
引用
- Nakajima K, Oguri M, Iwata H, et al. Long-term survival outcomes and quality of life of image-guided proton therapy for operable stage I non-small cell lung cancer: A phase 2 study. Radiother Oncol. 2024. PMID: 38614284. doi:10.1016/j.radonc.2024.110276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。